Positive news for Transgene and NEC with promising results for personalized cancer vaccine TG4050.

From GlobeNewswire: 2025-06-01 13:15:00

Transgene and NEC present positive data on TG4050, a personalized neoantigen therapeutic vaccine, at ASCO 2025. Results show all patients in the treatment arm with HPV-negative head and neck cancer remained disease-free after 2 years. TG4050 induced long-lasting immune responses and was well-tolerated. Phase I trial demonstrated proof of principle, leading to an extension to Phase II. This innovative therapy, powered by AI, aims to provide long-term value to patients. Ongoing trial aims to confirm results in a larger patient population. Conference call scheduled for more details on June 6, 2025.



Read more at GlobeNewswire: Transgene and NEC Present Durable Disease-Free Survival and